Core Insights - U.S. drugmaker Eli Lilly has signed an agreement with Seamless Therapeutics, a Germany-based startup, valued at up to $1.12 billion to develop and commercialize treatments for hearing loss [1] Company Summary - Eli Lilly is expanding its portfolio by partnering with Seamless Therapeutics to address hearing loss, indicating a strategic move into the audiology market [1] - The agreement highlights Eli Lilly's commitment to innovative therapies and its willingness to invest significantly in emerging technologies [1] Industry Summary - The collaboration reflects a growing interest in the treatment of hearing loss, an area that has seen limited advancements compared to other medical fields [1] - The deal underscores the potential for significant market opportunities in the hearing loss treatment sector, which may attract further investments and research [1]